Effect of endoscopic stenting of malignant bile duct obstruction on quality of life

Journal of Clinical Gastroenterology

Volumn 47, Issue 6, 2013, Pages 526-531

  Barkay, Olga ^a   Mosler, Patrick ^b   Schmitt, Colleen M ^c   Lehman, Glen A ^d   Frakes, James T ^e,f   Johanson, John F ^e   Qaseem, Tahir ^g   Howell, Douglas A ^h   Sherman, Stuart ^d  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^c Galen Medical Group   (United States)

^d INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF ILLINOIS   (United States)

^f Rockford Gastroenterology Associates Ltd   (United States)

^g Presbyterian Healthcare Services   (United States)

^h MAINE MEDICAL CENTER   (United States)

Author keywords

Biliary plastic stents; Jaundice; Palliation

Indexed keywords

ADULT; AGED; ARTICLE; CHOLESTASIS; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENDOSCOPIC STENT; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; STENT; WELLBEING;

AGED; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; CHOLESTASIS; DUODENOSCOPY; HUMANS; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES; PROSTHESIS IMPLANTATION; QUALITY OF LIFE; QUESTIONNAIRES; STENTS;

EID: 84879883379     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e318272440e     Document Type: Article

References (36)

1. Jemal A, Thomas A, Murray T, et al. Cancer statistics 2002. CA Cancer J Clin. 2002; 52: 23-47.
2. Lowy AM. From bad to worse: prognostic factors in pancreatic cancer. Ann Surg Oncol. 2004;11: 117-118.
3. Lowenfels AB, Maisonneuve P, Boyle P. Epidemiology of pancreatic cancer. In: Howard J, Idezuki Y, Ihse I, et al, eds. Surgical Diseases of the Pancreas. 3rd ed. Baltimore: Lippincott Williams & Wilkins; 1998: 433-439.
4. Speer A, Cotton P, Russell R, et al. Randomized trial of endoscopic versus percutaneous stent insertion in malignant obstructive jaundice. Lancet. 1987;2: 57-62.
5. Andersen J, Sorensen S, Kruse A, et al. Randomized trial of endoscopic endoprothesis versus operative bypass in malignant obstructive jaundice. Gut. 1989;30: 1132-1135.
6. Motte S, Deviere J, Dumonceau JM, et al. Risk factors for septicemia following endoscopic biliary stenting. Gastroenterology. 1991;101: 1374-1381.
7. Tarnasky PR, Cunningham JT, Hawes RH, et al. Transpapillary stenting of proximal biliary strictures: does biliary sphincterotomy reduce the risk of postprocedure pancreatitis? Gastrointest Endosc. 1997;45: 46-51.
8. Margulies C, Siqueira ES, Silverman WB, et al. The effect of endoscopic sphincterotomy on acute and chronic complications of biliary endoprostheses. Gastrointest Endosc. 1999; 49: 716-719.
9. Giorgio PD, Luca LD. Comparison of treatment outcomes between biliary plastic stent placements with and without endoscopic sphincterotomy for inoperable malignant commonbile duct obstruction. World J Gastroenterol. 2004;10: 1212-1214.
10. Johanson JF, Schmalz MJ, Geenen JE. Incidence and risk factors for biliary and pancreatic stent migration. Gastrointest Endosc. 1992;38: 341-346.
11. Speer A, Cotton P, Rode J, et al. Biliary stent blockage with bacterial biofilm. Ann Intern Med. 1988;108: 546-553.
12. Frakes J, Johanson J, Stake J. Optimal timing for stent replacement in malignant biliary tract obstruction. Gastrointest Endosc. 1993;39: 164-167.
13. Ballinger AB, McHugh M, Catnach SM, et al. Symptom relief and quality of life after stenting for malignant bile duct obstruction. Gut. 1994;35: 467-470.
14. Pereira-Lima JC, Jakobs R, Maier M, et al. Endoscopic stenting in obstructive jaundice due to liver metastases: does it have a benefit for the patient? Hepatogastroenterology. 1996;43: 944-948.
15. Luman W, Cull A, Palmer KR. Quality of life in patients stented for malignant biliary obstructions. Eur J Gastroenterol Hepatol. 1997;9: 481-484.
16. Abraham NS, Barkun JS, Barkun AN. Palliation of malignant biliary obstruction: a prospective trial examining impact on quality of life. Gastrointest Endosc. 2002;56: 835-841.
17. Sherman S, Lehman G, Earle D, et al. Multicenter randomized trial of 10 French versus 11.5 French plastic stents for malignant bile duct obstruction. Gastrointest Endosc. 1996;43: A421.
18. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy Scale: development and validation of the general measure. J Clin Oncol. 1993;11: 570-579.
19. Cheung YB, Goh C, Thumboo J, et al. Variability and sample size requirements of quality-of-life measures: a randomized study of three major questionnaires. J Clin Oncol. 2005;23: 4936-4944.
20. Steel JL, Eton DT, Cella D, et al. Clinically meaningful changes in health-related quality of life in patients diagnosed with hepatobiliary carcinoma. Ann Oncol. 2006;17: 304-312.
21. Hahn EA, Cella D. Unbiased quality of life measurement across literacy levels and mode of administration. Qual Life Res. 1997;6:654.
22. Yost KJ, Sorensen MV, Hahn EA, et al. Using multiple anchor- and distribution-based estimates to evaluate clinically meaningful change on the Functional Assessment of Cancer Therapy-Biologic Response Modifiers (FACT-BRM) instrument. Value Health. 2005;8: 117-127.
23. Webster K, Cella D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health Qual Life Outcomes. 2003;1:79.
24. Cella D, Li JZ, Cappelleri JC, et al. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. J Clin Oncol. 2008;26: 3763-3769.
25. Fairclough DL, Cella DF. Functional Assessment of Cancer Therapy (FACT-G): non-response to individual questions. Qual Life Res. 1996;5: 321-329.
26. Jaeschke R, Singer J, Guyatt G. Measurement of health status: ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10: 407-415.
27. Guyatt GH, Osoba D, Wu AW, et al. Methods to explain the clinical significance of health status measures. Mayo Clin Proc. 2002;77: 371-383.
28. Cella D, Hahn E, Dineen K. Meaningful change in cancerspecific quality of life scores: differences between improvement and worsening. Qual Life Res. 2002;11: 207-221.
29. Brucker PS, Yost K, Cashy J, et al. General population and cancer patient norms for the Functional Assessment of Cancer Therapy-General (FACT-G). Eval Health Prof. 2005;28: 192-211.
30. Rege RV. Adverse effects of biliary obstruction: implications for treatment of patients with obstructive jaundice. AJR Am J Roentgenol. 1995;164: 287-293.
31. Kramer HJ. Impaired renal function in obstructive jaundice: roles of the thromboxane and endothelin systems. Nephron. 1997;77: 1-12.
32. Jiang WG, Puntis MC. Immune dysfunction in patients with obstructive jaundice, mediators and implications for treatment. HPB Surg. 1997;10: 129-142.
33. Cotton PB, Schmitt C. Quality of life in palliative management of malignant obstructive jaundice. Scand J Gastroenterol. 1993;199: 44-46.
34. Moss AC, Morris E, Leyden J, et al. Malignant distal biliary obstruction: a systematic review and meta-analysis of endoscopic and surgical bypass results. Cancer Treat Rev. 2007;33: 213-221.
35. Yeoh KG, Zimmerman MJ, Cunningham JT, et al. Comparative costs of metal versus plastic biliary stent strategies for malignant obstructive jaundice by decision analysis. Gastrointest Endosc. 1999;49: 466-471.
36. Fitzsimmons D, Johnson CD. Quality of life after treatment of pancreatic cancer. Langenbecks Arch Surg. 1998;383: 145-151.